ONC 113 B

Drug Profile

ONC 113 B

Alternative Names: ONC 1-13B; ONC-10013B

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AllaChem
  • Developer AllaChem; Avionco
  • Class Antiandrogens; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Breast cancer

Most Recent Events

  • 03 Apr 2017 Chemical structure information added
  • 01 Apr 2017 Avionco completes a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Hormone-refractory) in Russia (PO) (NCT03074032)
  • 15 Mar 2017 Adverse events data from a preclinical trial in Prostate cancer and Breast cancer released by AllaChem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top